PREMIERE DATE: September 20, 2015
EXPIRATION DATE: March 20, 2017
This activity offers CE credits for:
1. Physicians (CME)
To understand how the changes in DSM-5 affect the diagnoses of somatic disorders and how to assess and treat a patient with somatic symptoms.
At the end of this CE activity, participants should be able to:
• Differentiate between DSM-5 somatic symptom and related disorders and DSM-IV somatoform disorders
• Incorporate DSM-5 criteria for somatoform disorder into their practice
• Understand the role of medically unexplained symptoms in somatic disorders
This continuing medical education activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.
CME Credit (Physicians): This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC, and Psychiatric Times. CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners and Physician Assistants: AANPCP and AAPA accept certificates of participation for educational activities certified for 1.5 AMA PRA Category 1 Credit™.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer-review process.
The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Maria Kleinstäuber, PhD, has no disclosures to report.
Winfried Rief, PhD, has no disclosures to report.
Katharina Voigt, PhD (peer/content reviewer), has no disclosures to report.
Applicable Psychiatric Times staff and CME Outfitters staff have no disclosures to report.
UNLABELED USE DISCLOSURE
Faculty of this CME/CE activity may include discussion of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity?
Call us at 877.CME.PROS (877.263.7767)
Dr Kleinstäuber is Assistant Professor of Clinical Psychology and Dr Rief is Professor of Clinical Psychology in the department of clinical psychology and psychotherapy at Philipps-Universität Marburg, Germany.
1. Rief W, Mewes R, Martin A, et al. Evaluating new proposals for the psychiatric classification of patients with multiple somatic symptoms. Psychosom Med. 2011;73:760-768.
2. Tomenson B, McBeth J, Chew-Graham CA, et al. Somatization and health anxiety as predictors of health care use. Psychosom Med. 2012;74:656-664.
3. Rief W, Nanke A, Emmerich J, et al. Causal illness attributions in somatoform disorders: associations with comorbidity and illness behavior. J Psychosom Res. 2004;57:367-371.
4. Rief W, Martin A. How to use the new DSM-5 somatic symptom disorder diagnosis in research and practice: a critical evaluation and a proposal for modifications. Annu Rev Clin Psychol. 2014;10:339-367.
5. Hiller W, Rief W. Abolishing the somatoform disorders by DSM-5—an academic piece of bungling? Psychotherapeut. 2014;59:448-455.
6. Frances A. DSM-5 somatic symptom disorder. J Nerv Ment Dis. 2013;201:530-531.
7. van Dessel N, den Boeft M, van der Wouden JC, et al. Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults. Cochrane Database Syst Rev. 2014;11:CD011142.
8. Kleinstäuber M, Witthöft M, Steffanowski A, et al. Pharmacological interventions for somatoform disorders in adults. Cochrane Database Syst Rev. 2014;11:CD010628.
9. Hausteiner-Wiehle C, Schäfert R, Sattel H, et al. New guidelines on functional and somatoform disorders [in German]. Psychother Psychosom Med Psychol. 2013;63:26-31.
10. Thomson AB, Page LA. Psychotherapies for hypochondriasis. Cochrane Database Syst Rev. 2007; 4:CD006520.
11. Fallon BA, Petkova E, Skritskaya N, et al. A double-masked, placebo-controlled study of fluoxetine for hypochondriasis. J Clin Psychopharmacol. 2008;28:638-645.
12. Fallon BA, Schneier FR, Marshall R, et al. The pharmacotherapy of hypochondriasis. Psychopharmacol Bull. 1996;32:607-611.
13. Greeven A, van Balkom AJ, Visser S, et al. Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis: a randomized controlled trial. Am J Psychiatry. 2007;164:91-99.
14. Martin A, Härter M, Henningsen P, et al. Evidence-Based Guideline for Psychotherapy for Somatoform Disorders. Göttingen, Germany: Hogrefe; 2012.
15. Kirmayer LJ, Taillefer S. Somatoform disorders. In: Turner SM, Hersen M, eds. Adult Psychopathology and Diagnosis. 3rd ed. New York: Wiley; 1997:333-383.
16. Lazarus RS, Launier R. Stress-related transactions between person and environment. In: Pervin LA, Lewis M, eds. Perspectives in International Psychology. New York: Plenum Press; 1978:287-327.
17. Salkovskis PM, Warwick HM. Morbid preoccupations, health anxiety and reassurance: a cognitive-behavioural approach to hypochondriasis. Behav Res Ther. 1986;24:597-602.
18. Warwick HM. A cognitive-behavioural approach to hypochondriasis and health anxiety. J Psychosom Res. 1989;33:705-711.
19. Borkovec TD, Ray WJ, Stöber J. Worry: a cognitive phenomenon intimately linked to affective, physiological, and interpersonal behavioral processes. Cognitive Ther Res. 1998;22:561-576.
20. Craske MG, Treanor M, Conway CC, et al. Maximizing exposure therapy: an inhibitory learning approach. Behav Res Ther. 2014;58:10-23.
21. Royal College of General Practitioners. Guidance for Health Professionals on Medically Unexplained Symptoms (MUS); January 2011. http://www.rcpsych.ac.uk/pdf/CHECKED%20MUS%20Guidance_A4_4pp_6.pdf. Accessed July 14, 2015.